Thank You for Visiting DIMA Biotech at PEGS & CAS 2025!

We had a fantastic time connecting with researchers, partners, and customers at PEGS Boston and the CAS 2025 Annual Meeting this May. Thank you to everyone who stopped by our booth, attended our talks, or picked up our materials—it was great to meet so many of you in person!

As a follow-up, we’ve created this page to share key resources, highlights, and moments from both conferences. Whether you’d like to revisit our materials or explore our latest innovations, everything is just a click away.

Explore Our Technologies & Platforms

Download our latest brochures, product highlights, and technical posters:

DIMA Highlight
Lead Antibody Molecules
Synthetic Nanodisc
Scan code download
About DIMA BIOTECH
CAS Meeting Poster

Conference Highlights

Check out some snapshots and videos from our time at PEGS and CAS:

Browse our categories

Latest News

Advances in STEAP1-Targeted Drug Development: T-Cell Engager Enters Phase III as ADC and CAR-T Programs Advance

The first STEAP1-targeted therapy, Xaluritamig, has delivered promising Phase III clinical results, achieving a PSA50 response rate of 59%. Multiple...

World’s First CAR-T Therapy for Solid Tumors Approved: How Can CLDN18.2 CAR Positivity Be Detected More Accurately?

The approval of the world’s first CAR-T therapy for solid tumors not only marks a new milestone in CAR-T treatment,...

2026 ASCO Target Review (Part III): Small-Molecule Targeted Therapy and Precision Oncology

Classic targets such as EGFR, RET, RAS, ER, and AR continue to evolve, while precision oncology advances from identifying driver...

2026 ASCO Target Review (Part II): Bispecific and Multispecific Antibodies and Immunotherapy Combinations

Bispecific antibody development is evolving beyond simply combining two targets, with T-cell engagers, PD-1×VEGF, PD-1×CTLA-4, and 4-1BB-based approaches emerging as...

2026 ASCO Target Review (Part I): ADCs

Beyond HER2 and TROP2, emerging targets such as CLDN18.2, B7-H3, FOLR1, and HER3 are rapidly gaining momentum, signaling a shift...

April–May 2026 Biopharma Deal Review: Multi-Billion-Dollar M&A Rebounds, $15.2B China Deal Leads Global BD Wave

From April to May 2026, global biopharma dealmaking rebounded, with major pharma focusing on de-risked assets and growing interest in...

TfR1/TFRC/CD71: From Iron Metabolism to a Gateway for Brain Delivery

With updated Phase III clinical data released by Roche in 2025, trontinemab has emerged as a leading example of TfR1-mediated...

From BD to Clinical Milestones The Core Trends in Autoimmune Diseases Finally Emerge in 2026 Q1

In Q1 2026, progress in the autoimmune field is no longer characterized by fragmented innovation, but by systematic breakthroughs centered...

What’s Next?

We’re excited to continue supporting your research through:

Currently, we offer over 500 in-stock Nanodisc products, covering more than 200 membrane protein targets, with a variety of tag options available (such as Flag, MBP, Strep, etc.) to meet diverse experimental needs. In addition to our catalog products, we also provide customized services, including biotin labeling, protein affinity binding analysis(SPR), and more, offering flexible support for your research workflows.

Our Nanodiscs provide a stable, native-like lipid bilayer environment for membrane proteins, making them ideal for applications such as membrane protein stabilization, structural biology(Cryo-EM), ligand screening, and antibody discovery.

Click to read our latest blog about Optimizing GPCR Expression and Purification.

At present, DIMA has developed B cell seed libraries and the corresponding pilot antibody molecules for around 500+ targets for blood tumor, immune checkpoints and solid tumors. All targets have human-rabbit chimeric antibodies, and 50+ targets have completed humanization antibodies developed by our DiLibrary™ display platform.

Contact US

If you missed us at the show or want to follow up, feel free to reach out—we’d love to hear from you!


    Please prove you are human by selecting the house.